about
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.Bortezomib is an efficient agent in plasma cell leukemias.ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyTherapeutic potential of ERK5 targeting in triple negative breast cancerERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.Neuregulins and cancer.Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic targetNeuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.Targeting the EGF/HER Ligand-Receptor System in Cancer.Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue.Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.Multifunctional role of Erk5 in multiple myeloma.The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation.The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzymeCleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated formsErk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosisNeuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer
P50
Q24531403-8E208278-6CC6-4DF9-BFEC-BA1CFC12E547Q30582030-DB662FC4-9DFE-4C86-AEDB-0013A7743C43Q33364213-477F9A76-FD18-477D-948B-7AF2867AD9B4Q33476874-3B47E2B1-6302-421B-AE2D-73060F8BD2F3Q34956816-BB6968F2-F4DB-4BD7-B426-E32130641156Q36879241-06560A4C-3769-46CD-B90D-847FE64680EBQ37179990-A243A34E-6C1A-4E4F-B6CB-F260654D563EQ37182453-4AF9A7FD-AE8B-4F92-AB6F-DD022238EF7DQ37564335-88495C7A-4088-4D9D-8D30-0A5AEB590C55Q38745576-70C4AAE8-2448-4779-80B3-11D1B049938FQ38899794-BC150C61-3FF0-49E4-952C-25DD0D36A3F3Q39196178-5FF0C3D8-F0AC-42D9-B3AD-AEF0E9F2AC1FQ39959245-52463F5E-11AC-4070-9A86-677F7C9FD127Q40740565-4407DABD-78B9-4555-A78B-679781FFC9A2Q42131728-E98A7AF3-2D05-4B81-B700-687AABF5E069Q45251392-B5BEAEF6-3D3B-4E0A-82DE-57ACD808C332Q46528752-47A36D75-3B0E-4D43-BA30-EDBE4DF6C204Q54325437-785AC40E-FC5E-48E3-8090-D268D190BD1FQ73204078-8E18A4D5-266B-41D8-85A9-795B5CDF3003Q74673079-D095000E-288A-431F-BF0D-23B9C4130377Q79816809-765AA821-7A64-44F1-A31F-69E1F1C4CFFFQ80548331-7669FAD8-3DEB-4DCD-8C3E-C2E1749DA241
P50
description
researcher, ORCID id # 0000-0003-4550-4192
@en
wetenschapper
@nl
name
Azucena Esparís-Ogando
@ast
Azucena Esparís-Ogando
@en
Azucena Esparís-Ogando
@es
Azucena Esparís-Ogando
@nl
type
label
Azucena Esparís-Ogando
@ast
Azucena Esparís-Ogando
@en
Azucena Esparís-Ogando
@es
Azucena Esparís-Ogando
@nl
prefLabel
Azucena Esparís-Ogando
@ast
Azucena Esparís-Ogando
@en
Azucena Esparís-Ogando
@es
Azucena Esparís-Ogando
@nl
P106
P21
P31
P496
0000-0003-4550-4192